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Case presentation
A 30-year-old white man, treated by chronic hemodialysis for 13
years, was hospitalized for evaluation of bone pain. At 3 years of age,
bilateral vesicoureteral refiux and hydronephrosis were discovered; the
BUN at that time was 45 mg/dl. At age 17, he began hemodialysis
treatments for 4 hours thrice weekly because of advanced renal
insufficiency. At that time, major physical findings included: short
stature; blood pressure, 160/90 mm Hg; a grade Il/Vi soft systolic
murmur localized in the left 5th intercostal space; and an arteriovenous
fistula in his left arm. Medications included B-complex vitamins,
hydralazine, alpha-methyldopa, calcium carbonate (1250 mg, 3 times
daily), and aluminum carbonate gel (3 to 4 capsules with each meal). At
age 23, he had a bilateral nephrectomy and a splenectomy in prepara-
tion for renal transplantation. At age 24 he received a cadaveric renal
transplant, but rejection necessitated transplant nephrectomy 20 days
later. Since then, he has done well while receiving hemodialysis
treatments 3 times per week.
For the past 3 years he has noticed a gradual increase in muscle and
bone pain, especially in his legs and particularly around the knees.
More recently he also has experienced severe bone pain in both
shoulders, The pain is aggravated by exercise and he has greatly
reduced his physical activities.
Laboratory examination revealed: hematocrit, 21%; hemoglobin, 7.2
g/dl; red blood cell count, 2 million/mm3; serum creatinine, 11.1 mg/dl;
BUN, 54 mgldl; serum phosphorus, 5.8 mg/dl; serum calcium, 10.2
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mg/dl; magnesium, 2.9 mg/dl; sodium, 141 mEq/liter; potassium, 5.1
mEq/liter; chloride, 107 mEq/liter; total C02, 20.2 mmol/liter; parathy-
roid hormone, 85 Eq/ml; and serum aluminum, 85 j.g/liter. Chest x-ray
showed mild cardiomegaly but no pulmonary infiltrates or pleural
effusions; the bones were diffusely osteopenic with prominent trabec-
ular markings. There was no evidence of bone erosion. Plain films of the
hands also revealed osteopenia without resorption or erosion of the
phalanges.
Because of the patient's long history of treatment with chronic
hemodialysis, his severe and diffuse bone pain, and the relatively low
levels of parathyroid hormone and high levels of serum aluminum, the
possibility of aluminum accumulation was considered highly likely.
Consequently, the patient was given deferoxamine (Desferal), 2 g,
intravenously as a diagnostic test. Within 36 hours, the serum aluminum
increased from 92 gJliter to 455 pg/liter. A bone biopsy revealed
aluminum in the interface between bone and osteoid tissue. Increased
amounts of osteoid tissue were present, the uptake of tetracycline was
abnormal, and the mineralization front was greatly diminished.
Treatment was begun with intravenous deferoxamine, 2 g per dialysis
(6 g/week). By 4 months after starting treatment, the patient's com-
plaints had diminished considerably. Muscle pain had largely disap-
peared except for mild discomfort in his legs. He has been able to
increase his physical activities considerably and has resumed an exer-
cise program.
Discussion
DR. EDUARDO SLATOPOLSKY (Professor of Medicine, Wash-
ington University School of Medicine; Director, Chromalloy
American Kidney Center, St. Louis, Missouri): This man illus-
trates one of the major complications observed in patients
treated with chronic hemodialysis. These patients frequently
complain of bone and joint pain as well as severe muscle
weakness, and physical activity often is limited by these symp-
toms. In some instances, pathologic fractures occur and com-
pound the problem. In the aggregate these symptoms, although
nondiagnostic, strongly suggest the presence of renal osteodys-
trophy, a syndrome resulting from a variable amalgam of bone
pathologies. The pathologic manifestations of renal osteodys-
trophy include:
(I) Osteitis fibrosa, characterized by an increase in osteo-
clasts, increased bone resorption, increased bone formation,
increased peritrabecular marrow fibrosis, and an abundance of
woven bone. This disorder is a consequence of the effects of
augmented parathyroid hormone (PTH) secretion on bone.
(2) Osteomalacia, a defect in bone mineralization character-
ized by wide lamellar osteoid seams, a paucity of osteoblasts
and osteoclasts, and an abnormal or absent mineralization
front. Although for many years alterations in vitamin D metab-
olism, profound acidosis, and hypophosphatemia were the
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three main factors considered responsible for the development
of osteomalacia, we now know that aluminum accumulation
plays a key role in the genesis of this bony disorder in dialysis
patients (Fig. 1).
(3) Osteosclerosis and osteoporosis, two less important types
of renal osteodystrophy, that I will not discuss today.
Phosphate retention and secondary
hyperparathyroidism
Although the pathway by which phosphate retention pro-
duces secondary hyperparathyroidism remains controversial,
no one doubts that prevention of phosphate retention during
renal insufficiency prevents the development of secondary
hyperparathyroidism. Several investigators have shown the
importance of controlling phosphorus in patients with chronic
renal failure and in animals with experimental renal disease
[1—4]. After end-stage renal disease (ESRD) is present, how-
ever, correction of hyperphosphatemia alone does not reverse
secondary hyperparathyroidism completely, because many
other factors presumably are at play.
Although hyperphosphatemia itself does not cause the acute
release of parathyroid hormone, it plays an important role in the
regulation of PTH secretion by inducing changes in serum
ionized calcium and in l,25(OH)2D3 levels [5]. An opposite
reciprocal relationship exists between serum ionized calcium
and serum phosphorus, and precipitation of calcium is known to
occur when the plasma phosphorus level increases. Even in
normal animals, secondary hyperparathyroidism can be in-
duced by feeding large amounts of phosphorus [6—8].
Phosphate retention also plays an important role in the
regulation of vitamin D metabolism. Phosphorus is a physio-
logic inhibitor of renal 1—hydroxylase, the enzyme responsible
for the conversion of 25(OH)D3 to l,25(OH)2D3 [5]; thus
retention of phosphate in patients with chronic renal failure
might contribute directly to the decreased levels of serum
1 ,25(OH)2D3 characteristic of this condition by inhibiting renal
1—hydroxylase [9, 10]. We know that l,25(OH)2D3 plays an
important role in the regulation of calcium absorption in the
intestinal tract; low levels of this metabolite of vitamin D are
responsible for the calcium malabsorption in patients with
advanced renal failure [11]. Recently, l,25(OH)2D3 has been
shown to play a key role in the regulation of the synthesis [12]
and secretion of parathyroid hormone [13—15]. The parathyroid
glands in patients with renal failure and low levels of
l,25(OH)2D3 are less sensitive to calcium than normal; as a
consequence, uremic patients require a greater increase in the
concentration of serum calcium to suppress parathyroid hor-
mone release [16]. This abnormality is referred to as a "shift in
the set point for calcium." In addition, high levels of serum
phosphorus [17] and low concentrations of circulating
l,25(OH)2D3 [18] make the skeleton more resistant to the action
of parathyroid hormone; as a result, a higher circulating level of
PTH is required to maintain normal serum calcium.
We recently have demonstrated yet another role for phos-
phorus in the pathogenesis of secondary hyperparathyroidism,
one that is independent of its effects on 1 ,25(OH)2D3 produc-
tion. Uremic dogs fed a low-phosphate diet did not develop
secondary hyperparathyroidism despite a significant decrease
in circulating l,25(OH)2D3. However, when dietary phosphate
Fig. 1. Photomicrographs showing representative features of alumi-
num-induced osteoma/acia. A Normal trabecular bone (undecalcified
Goldner stain, magnification x 57). B = bone; 0 = osteoid. B Wide
osteoid seams (0) (undecalcified Goidner stain, magnification x 100). C
Low-power view of trabecular bone stained for aluminum. The alumi-
num stains as a bright red band at the junction between mineralized
bone and wide osteoid seams. (Courtesy of Stephen L. Teitelbaum,
M.D., St. Louis, Missouri.)
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was increased, IPTH levels increased severalfold [19]. We also
demonstrated that the abnormal calcemic response to PTH in
dogs with chronic uremia is not improved by the administration
of pharmacologic doses of I ,25(OH)2D3 [201. These observa-
tions confirm results obtained in rats with acute renal failure
[21]. On the other hand, when a parathyroidectomy was per-
formed 24 hours before the administration of PTH, the calcemic
response was normal. These results suggest that high levels of
endogenous PTH desensitized the skeleton to the effects of
exogenous PTH,
Phosphate retention thus contributes in many ways to the
pathogenesis of secondary hyperparathyroidism in chronic re-
nal failure. For this reason, as well as for prevention of other
deleterious effects of hyperphosphatemia (such as metastatic
calcifications, pruritis, vascular insufficiency, and arthritis),
phosphorus levels must be controlled in patients with chronic
renal failure. Phosphorus absorption from the gastrointestinal
tract can be markedly decreased either by decreasing the
amount of phosphorus in the diet or by administering phos-
phate-binding agents capable of decreasing the absorption of
phosphorus. In patients with moderate renal insufficiency,
phosphate balance can be maintained easily by moderately
restricting protein-containing foods. Because protein require-
ments limit the degree to which phosphorus can be restricted
through dietary manipulations, administration of agents capable
of decreasing gastrointestinal absorption of phosphorus has
become the mainstay of treatment in patients with hyperphos-
phatemia.
Aluminum-containing phosphate hinders
The oral administration of phosphate binders containing
aluminum has been the conventional method of controlling
hyperphosphatemia. Aluminum hydroxide and aluminum car-
bonate gels, the two most commonly used agents, were as-
sumed until recently to be nonabsorbable and safe. We now
know, however, that the oral administration of these salts
results in significant absorption of aluminum in humans and in
experimental animals with renal insufficiency, and that such
treatment can produce increased plasma and tissue aluminum
concentrations. Kaehny and collaborators demonstrated that
subjects with normal renal function who ingest phosphate
binders containing aluminum increase the amount of aluminum
in the urine from approximately 15 gIday to values in the range
of 250 to 350 g!day [221. If we reason from this observation, we
find that patients with advanced renal disease—especially those
being treated with hemodialysis—could retain large amounts of
aluminum in their body over a period of time.
Berlyne and colleagues raised the possibility several years
ago that phosphate binders were an important source of alumi-
num [23]. Studies indicate that patients treated with aluminum
hydroxide or aluminum carbonate gels absorb small amounts of
aluminum and that, in the presence of renal failure, aluminum
retention occurs because the kidney is the only excretory route.
We know that aluminum can accumulate in clinically significant
amounts as a consequence of oral ingestion of aluminum
hydroxide. Several examples of aluminum-related osteomalacia
have occurred in uremic patients who had never been dialyzed
but who had been treated with aluminum hydroxide [24—26].
Studies also suggest that plasma aluminum levels correlate
closely with the quantity of aluminum gel ingested by children
on dialysis [27]. When dialysis patients discontinue taking
aluminum-containing gels, plasma aluminum levels fall substan-
tially [28]. This finding provides evidence that intestinal absorp-
tion plays an important role in aluminum accumulation. Be-
cause hemodialysis can prolong life for extended periods, it is
not unusual to encounter patients who have been ingesting
phosphate binders for 10 years or more. Epidemiologic studies
show that a large number of patients maintained for 4 years or
longer on hemodialysis using treated water may have accumu-
lated large amounts of aluminum in their body [29]. Thus,
ingestion of phosphate-binding gels appears to be the most
important source of aluminum in patients maintained on chronic
hemodialysis.
Dialysis-related aluminum accumulation
Many abnormalities in patients with renal failure appear to be
the consequence of chronic aluminum administration. Among
the findings associated with aluminum accumulation are bone
and joint pain, muscle weakness, and pathologic fractures; as a
rule, none of these abnormalities respond to treatment with
vitamin D metabolites. Patients with aluminum accumulation
usually have normal or slightly elevated serum calcium levels
and frequently develop hypercalcemia when they are treated
with small doses of I ,25(OH)2D3 [29]. Further, dialysis patients
with aluminum accumulation have lower-than-expected serum
levels of iPTH [28, 30—33] (Fig. 2), and these levels fail to
increase after the induction of hypocalcemia [31, 32]. In addi-
tion patients with aluminum accumulation may have other
symptoms indicating an effect of aluminum on the central
nervous system. They may have speech disturbances charac-
terized by stuttering and mild disorientation. As the disease
progresses, patients may develop aluminum-induced encepha-
lopathy. This disorder is characterized by marked changes in
personality, twitching, myoclonus, progressive dementia termi-
nating in convulsions, and death. Early in the disease, the EEG
shows multifocal bursts of delta activity, mixed with runs of
normal-appearing background activity. Usually the changes in
the EEG precede the clinical findings by 3 to 6 months. The
diagnosis of aluminum-induced encephalopathy depends on the
presence of the typical clinical picture and the characteristic
EEG pattern.
Definition of aluminum-induced osteomalacia
Although most of the patients with aluminum-induced
osteomalacia have clinical findings characterized by bone and
joint pain, muscle weakness, and pathologic fractures, a bone
biopsy is required to make a definitive diagnosis. The use of the
double tetracycline label will demonstrate an abnormal miner-
alization front. Stainable aluminum localized in the mineraliza-
tion front will further indicate that the abnormal mineralization
process is due to aluminum accumulation. Two main forms of
aluminum-induced osteomalacia have been described. The
more common form is characterized by an increase in the
volume of osteoid. The less common form is characterized by a
normal or reduced amount of osteoid. As previously indicated,
both forms have an abnormal uptake of tetracycline.
Epidemiology
The initial outbreak of dialysis osteomalacia occurred in
geographic areas in which aluminum levels in water exceeded
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Fig. 2. Serum i-PTH in a group of dialysis patients with mild, moder-
ate, and severe secondary hyperparaihyroidism. CH9 antibody (pre-
dominantly a mid-region and carboxy-terminal antibody) was used in
this study. There was an excellent correlation between i-PTH and bone
histomorphometric results. Patients with aluminum-induced osteoma-
lacia (0) have low levels of i-PTH. Only 8% of 100 patients with
aluminum-induced osteomalacia have high levels of i-PTH.
100 gIliter [34]. Subsequent experience, however, revealed a
high incidence of aluminum-induced bone disease in patients
exposed to dialysate with aluminum levels only as high as 50
pg/liter. Kaehny and colleagues studied the transfer of alumi-
num during hemodialysis [35]. Predialysis plasma concentration
in 16 patients in whom low aluminum dialysate was used
averaged 58 g/1iter with a postdialysis mean of 63 gIliter. In
19 patients in whom a high aluminum dialysate was used, mean
predialysis plasma aluminum concentration was 168 pg/liter and
the postdialysis level was 265 g/1iter. The authors concluded
that a significant amount of aluminum can be transferred to
plasma during dialysis if the dialysate contains virtually any
aluminum because aluminum, which is approximately 90%
protein bound, becomes bound to plasma proteins. The high
degree of protein binding also limits the amount of aluminum
that can be removed from serum during dialysis.
Similar results were reported by Ricanati and coworkers,
who studied a group of patients before and after the introduc-
tion of a water purification system for preparing dialysate [36].
Before water purification was introduced, the plasma aluminum
in their patients ranged from 91 to 297 gIliter. The dialysate
aluminum levels varied widely from day to day; values ranged
between 40 and 85 gIliter and, over a 6—month period, levels
ranged from 10 to 170 g/liter. Kinetic studies during hemodi-
alysis indicated that aluminum influx from dialysate to patient
averaged 3.5 0.75 g/min. Plasma aluminum increased from a
mean of 179 97 pg/liter before dialysis to a mean of 281 110
ig!liter after dialysis. When they introduced a distillation
system for water treatment, the dialysate aluminum was main-
tained at levels less than 20 .tg/liter, and the patients' plasma
aluminum levels fell by 54 21% at five months and 43 9%
at one year.
As I mentioned, aluminum is highly protein bound, so even a
relatively low concentration of aluminum in the dialysate re-
sults in the transfer of aluminum into the patient. To prevent the
entrance of aluminum during dialysis, the recommended maxi-
mum concentration of aluminum in the dialysate now is less
than 10 gig/liter. Indeed, most of the dialysis units in the United
States now purify the water they use by reverse osmosis,
demineralization, or deionization, all of which reduce the
aluminum concentration to very low levels. At present the
major source of aluminum in patients with ESRD is not dialy-
sate but aluminum-containing phosphate binders.
Thus, two forms of aluminum-related bone disease have been
described [37]. One is an "epidemic" form arising from dialysis
with aluminum-containing water; the second is a "sporadic"
variant due to ingestion of aluminum hydroxide. With "epi-
demic" aluminum-related bone disease, the symptoms ap-
peared earlier than in sporadic cases. The incidence of enceph-
alopathy (41%) with "epidemic" aluminum exposure is much
higher than the 6.0% in patients with sporadic disease. The
fracture prevalence did not differ between the two forms, and
the tendency toward hypercalcemia and low or normal iPTH
levels were not different [37]. Llach and coworkers performed
bone biopsies in 142 hemodialysis patients [38]. The mean
duration of maintenance hemodialysis in these patients was 54
37 months. Of the 142 patients, 96 were found to have osteitis
fibrosa, 36 osteomalacia, and 10 aplastic bone disease. The
incidence of muscle weakness and bone pain was low in
patients with osteitis fibrosa (4% to 5%) when compared with
that of patients with osteomalacia (35% to 40%). Obviously,
there were significant histomorphometric differences of the two
diseases (osteitis fibrosa versus osteomalacia) in the bone
biopsy. The high incidence of osteomalacia was unexpected
because of historically acceptable concentrations of aluminum
in the dialysate. A high incidence (26%) of aluminum-induced
osteomalacia also was found by Ihie and coworkers [391.
The effect of aluminum on parathyroid hormone
secretion
Serum levels of iPTH are lower in dialysis patients who have
aluminum accumulation than in those who do not [28, 30—33]
(Fig. 2). Whether serum iPTH levels are lower in dialysis
patients with aluminum accumulation because aluminum exerts
a direct effect on the parathyroid glands or because serum
calcium concentrations are relatively high in this group is
unclear. Hemodialysis patients with aluminum-induced osteo-
malacia also experience a smaller increment in parathyroid
hormone secretion in response to hypocalcemia as compared
with such patients without aluminum-related osteomalacia [31,
32] (Fig. 3).
Morrissey and coworkers reported that aluminum directly
inhibits parathyroid hormone secretion by collagenase-
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dispersed bovine parathyroid cells [40]. Aluminum appeared to
act on the secretory process itself, because neither total protein
synthesis, the biosynthesis of proparathyroid hormone, nor the
conversion of proparathyroid hormone to parathyroid hormone
seemed to be affected by aluminum. These studies also demon-
strated that the suppression of PTH release by aluminum was
not due to an irreversibly toxic effect of aluminum. Parathyroid
hormone secretion returned to normal when the cells were
removed from the aluminum-containing medium and were
placed in a low-calcium medium without aluminum. In these
studies, large doses of aluminum were necessary to inhibit PTH
secretion. However, the majority of the aluminum used in the
incubation solution precipitated out, leaving a concentration of
aluminum that probably was in the range of aluminum levels
that are encountered clinically. In other studies, aluminum was
measured in the medium [411. In the presence of a calcium
concentration of 0.5 mM, increasing the concentration of alu-
minum from 29 to 135 ig/liter caused a 49% decrease in PTH
secretion. Increasing the calcium concentration from 0.5 to 2.0
mM caused a 42% suppression of hormone secretion (Fig. 4).
Both aluminum and calcium appear to inhibit parathyroid
hormone secretion by decreasing diglyceride levels in parathy-
roid cells [411; a fall in diglyceride inhibits protein kinase C
activity, which normally drives hormone secretion.
Of interest is that aluminum inhibits PTH secretion more than
calcium does at 2.0 mM concentrations in the medium. Alumi-
num ion interferes with calcium movement in smooth muscle
cells in a manner similar to that of lanthanum. Aluminum
therefore might interfere with calcium ion movements into and
out of the parathyroid cells. If aluminum inhibits calcium
movement out of the cell, the accumulation of cytosolic cal-
cium—even at a low ionic calcium concentration in the me-
dium—ultimately would inhibit parathyroid hormone secretion.
Similar results were obtained by Bourdeau and collaborators in
studies performed with porcine parathyroid gland slices incu-
bated in low concentrations of aluminum [42]. Dietel and
Fig. 4. The effect of aluminum on parathyroid hormone secretion from
dispersed parathyroid cells. The cells were incubated at a density of
200,000 cells/mi at the indicated calcium concentrations with variable
aluminum ion concentrations (solid bars). The incubations were termi-
nated after 2 hours. Aluminum at the concentration of 135 pg/liter
produced a 49% suppression of PTH secretion. (Modified from Ref. 38.)
coworkers further characterized the role of aluminum and other
factors in the regulation of parathyroid hormone secretion [43];
their results also indicated that aluminum had an effect on
cytosolic calcium. Parathyroid glands obtained from uremic
patients or uremic rats that had received aluminum accumu-
lated it in higher concentration than did either thyroid or muscle
[44]. Bellorin-Font and collaborators studied the potential
mechanisms by which aluminum might suppress the release of
parathyroid hormone [45]. Aluminum added to the medium
bathing membranes from normal bovine parathyroid glands
caused a progressive decrease in adenylate cyclase activity.
Because adenylate cyclase activation is influenced by multiple
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Fig. 3. A comparison of PTH response to
hypocalcemia in patients with osteomalacia
(0) versus patients with osteitis fibrosa (s).
A The amino terminal i-PTH response was
significantly greater at 30, 60, 90, and 120
minutes in osteitis fibrosa (•). B Similar
results are depicted with a carboxy-terminal
PTH assay. (Reproduced from Ref. 32.)
n=5
Ionized Ca 0.5mM I Ca 2.0mM
a,C'
0
II-0.
0(C
22
20
18
16
14
12
10 IIIT _
Aluminum, hg/liter
a
Parathyroid hormone and aluminum in osteodyszrophy 847
reactions within the adenylate cyclase complex, this group
explored the interaction of aluminum with substrate ATP and
with magnesium. Their data suggest that inhibition of parathy-
roid adenylate cyclase by aluminum occurs at the level of the
allosteric metal activating site. These observations provide a
potential mechanism by which aluminum might inhibit PTH
secretion.
The aluminum-parathyroid-bone axis
The mechanism by which aluminum accumulation results in
the development of osteomalacia remains uncertain. The pres-
ence of aluminum along the bone mineralization front in af-
fected individuals suggests that aluminum prevents mineraliza-
tion. In-vitro studies suggest that aluminum can prevent both
the generation and the growth of hydroxyapatite crystals [46].
Aluminum also might alter the function and number of osteo-
blasts [47, 48], the cells responsible for the formation of osteoid
tissue. Bone biopsies stained for aluminum by the aurin
tricarboxylic method have demonstrated this metal at the
interface between osteoid and bone as well as at cement lines
[49]. As an aside, the finding of aluminum in the interface is
critical in the diagnosis of aluminum-induced osteomalacia.
Two main forms of aluminum-induced osteomalacia have
been described [50]. The more common form is characterized
by an increase in the volume of osteoid and by reductions in the
rate of bone formation (as assessed by the double tetracycline
labeling technique). The abnormal uptake of tetracycline indi-
cates a defect in mineralization. The less common form of
aluminum-induced osteomalacia, characterized by a normal or
diminished amount of osteoid, also has been termed "aplastic
osteomalacia" [50]. As in other forms of osteomalacia, the
uptake of tetracycline is greatly reduced.
Whether determining aluminum content in bone has more
diagnostic value than does histochemical staining and quantify-
ing aluminum at the mineralization front is yet to be deter-
mined. Malluche and coworkers studied 55 patients on chronic
maintenance dialysis and correlated histopathologic parameters
of bone, bone aluminum content, and extent of staining bone
aluminum at the mineralization front [51]. These authors con-
cluded that staining bone aluminum is a more useful procedure
than is measuring aluminum content in assessing the extent of
aluminum-associated bone disease. They reasoned that bone
aluminum content reflects the total concentration of aluminum
in bone irrespective of its localization [51], whereas stainable
bone aluminum mainly reflects aluminum deposits localized at
the mineralization front.
Although most researchers agree that aluminum is toxic for
bone and that its accumulation can cause osteomalacia, some
investigators argue that the aluminum in the osteoid tissue is
simply an epiphenomenon and that it is not the factor respon-
sible for the development of osteomalacia. Quarles and associ-
ates induced osteomalacia in dogs by depriving them of vitamin
D [521. After bone disease was established, aluminum, which
was given to the animals, appeared in the already abnormal
osteomalacic bone. Subsequent administration of vitamin D
induced a rise in plasma calcium and phosphorus levels to
normal and the osteomalacia healed. The appearance of alumi-
num in the cement lines of the healed bones indicated that
mineralization had occurred at sites of prior aluminum deposi-
tion [52]. It is important to note, however, that this experimen-
tal model is not entirely relevant to patients with chronic renal
insufficiency. Bone disease in rats with vitamin D-deficient
rickets heals when serum calcium and phosphorus return to
normal, even when vitamin D deprivation persists [53]. On the
other hand, when serum calcium or phosphate is increased in
patients with aluminum-induced osteomalacia, bone disease
does not improve. Moreover, administration of l,25(OH)2D3 to
these patients can cause hypercalcemia but does not alleviate
the basic abnormality (osteomalacia) unless aluminum is re-
moved from the bone (for example, by deferoxamine treat-
ment).
The concentration of parathyroid hormone in the serum is yet
another factor of interest. Low levels of PTH activity appear to
predispose to the development of osteomalacia [54—56]. More-
over, uremic patients have an increased incidence of mineral-
ization defects after undergoing parathyroidectomy [30, 33,
57—59]. All changes characteristic of osteitis fibrosa improve
greatly after parathyroidectomy, but in some patients a miner-
alization defect develops that was not apparent before parathy-
roidectomy. Because parathyroid hormone plays a key role in
the regulation of the coupled process of bone formation and
resorption, subtotal parathyroidectomy, with its sudden, sub-
stantial reduction in circulating parathyroid hormone, is likely
to impair this coupled process greatly. We were the first to draw
attention to the mineralization defect sometimes seen in uremic
patients after parathyroidectomy; we described 2 patients with
total parathyroidectomy in whom administration of vitamin D
metabolites failed to cure or improve osteomalacia [60]. The
lack of parathyroid hormone apparently predisposes to an
increased accumulation of aluminum in the interface between
osteoid and bone. This deposition greatly increases the risk for
the development of osteomalacia. The mechanism of this effect
of parathyroid hormone deficiency is unknown, but the reduc-
tion in number and function of the osteoblasts and the decrease
in bone formation following parathyroidectomy may, in some
undetermined fashion, permit aluminum accumulation.
Noninvasive diagnostic procedures for
aluminum-induced osteomalacia
Bone biopsy is the definitive test for unequivocally establish-
ing the diagnosis of aluminum-induced osteomalacia. Because
this test is invasive, not universally available, and expensive,
efforts have been made to develop noninvasive tests to indi-
rectly assess the degree of aluminum accumulation. The admin-
istration of deferoxamine, a chelating agent that can mobilize
aluminum from bone and other tissues, can serve as a diagnos-
tic as well as a therapeutic tool for aluminum accumulation.
Milliner and colleagues studied a large number of patients
before and after administration of deferoxamine and correlated
these results with bone histomorphometry [33], They found a
significant difference in the basal levels of serum aluminum
between patients with aluminum-related bone disease (199
gIliter) and those with non-aluminum-related bone disease (93
gIliter), but there was substantial overlap in serum levels
between the two groups. After administration of deferoxamine,
they observed a remarkable increase in serum aluminum; the
level peaked between 18 and 24 hours and remained elevated
for 36 to 48 hours (Fig. 5). Patients with aluminum-related
osteodystrophy documented by bone histomorphometry had a
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a parathyroid hormone concentration of greater than 150
dEq/ml and an increment in plasma aluminum after deferox-
amine of less than 200 p.glliter had aluminum bone disease (Fig.
6). These studies suggest that an increment in plasma aluminum
concentration of less than 200 p.g/liter after administration of
deferoxamine argues strongly against the presence of alumi-
num-related osteodystrophy; only 5% of patients with alumi-
num-related osteodystrophy did not increase plasma aluminum
to more than 200 tg/liter in the test. The advantages of this test,
of course, are its noninvasive nature, its simplicity, and its
utilization of a generally well-tolerated drug.
Malluche and collaborators 151] also studied the diagnostic
value of serum aluminum levels and their changes after an
infusion of deferoxamine, but their data are less clearcut than
are those of Milliner [33]. They studied 12 patients with, and 10
patients without, aluminum accumulation in bone. Baseline
serum aluminum levels were higher in patients with bone
aluminum accumulation, but patients with aluminum accumu-
lation in bone could not be distinguished on this basis alone
because the overlap was so great. In those with aluminum
accumulation, serum aluminum levels rose consistently after
0 deferoxamine infusion. In those without aluminum accumula-0 tion, serum levels also rose but to a more variable degree.
Malluche's group concluded that the deferoxamine test cannot0 be used to diagnose aluminum accumulation in bone [51]. The
increase in serum aluminum induced by deferoxamine in pa-
tients without aluminum-induced osteomalacia was thought to
be due to the ability of deferoxamine to release aluminum from
organs other than bone.
I believe it is possible to identify those patients who are
particularly likely to have, and those who are particularly likely
not to have, aluminum accumulation. Although more work is0 needed to establish the diagnostic value of a given increment in
400 0 serum aluminum after deferoxamine administration, I believe
A the test can be used to identify most patients at risk for2 aluminum toxicity. I use these guidelines: If the basal aluminum
200 level is less than 50 jsglliter and if the increment afterU AA deferoxamine infusion is less than 200 sgIliter, it is likely that
A the patient has not retained a substantial amount of aluminum inI the body. Conversely, if the basal aluminum is greater than 150
I I I I I I
sg/liter, or if the increment in serum aluminum after deferoxa-150 300 450 600 750
mine administration is greater than 300 .g/liter, it is highly
Serum iPTH, IEq/m/ likely that the patient has retained a substantial amount of
Fig. 6. Relationship between the increment in plasma aluminum con- aluminum. Obviously, many patients fall between these two
centration after deferoxamine administration and i-PTH in patients extremes and pose a more difficult diagnostic problem that can
with aluminum-related osteodystrophy (0), non-aluminum-related ° be resolved with certainty only by a bone biopsy.
teodystrophy (A), and atypical cases (•). (Reproduced from Ref. 33.)
peak value of plasma aluminum after deferoxamine of 733 326
p.g/Iiter, whereas those known not to have aluminum bone
disease had a peak value of 307 122 pg/liter. The increment in
plasma aluminum concentration after deferoxamine infusion
correlated well with bone aluminum content, measured either
by histochemical staining or by atomic absorption spectrome-
try. Of interest, 30 of the 33 patients with a serum immunoreac-
tive parathyroid hormone concentration of less than 150
piEq/ml and an increment in plasma aluminum concentration
after deferoxamine of greater than 200 p.glliter had aluminum-
related osteodystrophy. By contrast, none of the patients with
Prevention and treatment of aluminum-induced
osteomalacia
There is little doubt that controlling phosphate balance is
mandatory in preventing renal osteodystrophy. Because com-
mercially available phosphate binders composed of aluminum
salts are partly responsible for the development of aluminum-
related osteomalacia, alternative ways of controlling phosphate
are urgently needed if the deleterious effects of aluminum on the
brain and skeleton are to be prevented. Calcium carbonate is a
possible substitute for aluminum-containing antacids. Approx-
imately 20 years ago, Clarkson and coworkers demonstrated
that the ingestion of calcium carbonate in large amounts by
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normal subjects and by patients with chronic renal failure
resulted in positive calcium balance and in less phosphate
absorption by the gastrointestinal tract [61]. When Makoff and
collaborators administered calcium carbonate to 20 uremic
patients for treatment of acidosis and hypocalcemia, the serum
phosphorus decreased from a mean of 8.1 3.6 mg/dl to 5.9
2.4 mg/dl within two to four weeks [62]. The patients found
calcium carbonate palatable and none complained of constipa-
tion. Moriniere and colleagues substituted high doses of oral
calcium carbonate for aluminum hydroxide in 26 patients main-
tained on chronic hemodialysis [63]. The dose of calcium
carbonate was increased progressively from approximately 4 to
10 g daily to maintain serum phosphate below 6 mg/dl and
plasma calcium below 10.5 mg/dl. Treatment was discontinued
in only 3 patients because of diarrhea or uncontrolled hyper-
phosphatemia. In the remaining patients, control of hyperphos-
phatemia and iPTH levels was as good or better than during
treatment with aluminum hydroxide. Serum aluminum levels,
moreover, fell to normal in most patients, demonstrating that
aluminum hydroxide gels had been responsible for hyper-
aluminemia. To evaluate the role of calcium carbonate as a
phosphate-binding agent in children maintained on continuous
ambulatory peritoneal dialysis (CAPD), Salusky and coworkers
studied 10 uremic children ranging in age from 6 months to 10.5
years [64]. After 8 to 18 months of calcium carbonate treatment,
the serum calcium was 10.2 6.0 mg/dl; phosphorus, 5.2 0.7
mg/dl; and CO2. 22 2mEq/liter. Plasma aluminum fell from 96
51 to 36 22 pg/liter. The mean daily dose of calcium
carbonate was 5.7 g and ranged between 2.5 and 12.8 g/24
hours. There were 8 instances of mild hypercalcemia (serum
calcium between 11.0 and 11.5 mg/dl), but none of the patients
developed symptoms or signs of hypercalcemia and none de-
veloped uncontrolled hyperphosphatemia, metabolic alkalosis,
or diarrhea. These studies indicate that calcium carbonate is an
effective phosphate-binding agent in children on dialysis and
could be used as an alternative to aluminum-containing gels.
Lopez and colleagues demonstrated the effects of calcium
carbonate on phosphate absorption in normal and uremic dogs
[651. In the first part of the study, phosphorus, 50mg/kg of body
weight, was given orally, and blood and urine samples were
obtained hourly. After one week, the study was repeated, but
calcium carbonate, 1.5 g/kg body weight, was added to the
phosphorus load. When phosphorus was given alone, the
increment in serum phosphorus was approximately 4.0 mg/dl;
when phosphorus plus calcium carbonate was given to the same
animals, the increment in serum phosphorus was only 1.9
mg/dl. Approximately 550 mg of phosphorus was excreted in
the urine over a 7-hour period when phosphorus was given
alone, whereas only 280 mg was execreted when phosphorus
was given with calcium carbonate. The ingestion of calcium
carbonate thus clearly can reduce phosphorus absorption.
In evaluating the effects of any intervention on phosphorus
absorption in humans, one must be careful to determine not
only the total amount of phosphorus ingested per 24 hours, but
also the amount ingested during each meal. Even though 2
patients might ingest the same amount of phosphorus in a given
day, the temporal profile of phosphorus intake might differ and
could greatly influence the efficacy of phosphate binding. For
example, let us assume that one patient eats a small breakfast
containing 60 mg of phosphorus, whereas another patient eats a
breakfast containing ham, eggs, and milk, and thus consumes
400 to 500 mg of phosphorus at this one sitting. The second
patient clearly would require more phosphate binder in the
morning than would the first to achieve the same control of
serum phosphorus.
We studied the effects of calcium carbonate (Os-Cal) in 20
patients maintained on chronic hemodialysis [661. The mean
phosphorus intake of these patients was approximately 900
mg/24 hours, but the variation in intake ranged between 600 and
1800 mg/24 hours. Thus the total amount of calcium carbonate
we gave to these patients ranged from 2.5 to 17.0 g/24 hours; the
mean value was 8.5 g 24/hours. The study was divided into
three parts: (1) For one month, the patients were maintained on
their usual aluminum-containing, phosphate-binder regimen. (2)
Over the subsequent one month, administration of the phos-
phate binder containing aluminum was discontinued. (3) During
the final two months of the study, calcium carbonate (Os-Cal)
was administered. In this period phosphate binders were added
only when necessary. Plasma calcium, phosphorus, and para-
thyroid hormone levels were determined 3 times weekly
throughout the study. Mean serum phosphorus was 4.8 0.13
mg/dl during the control period, 7.3 0.26 mgldl after the
aluminum-containing phosphate binders were discontinued,
and 4.8 0.7 mg/dl when calcium carbonate was given. Serum
calcium was 9.6 0.15 mg/dl during treatment with aluminum-
containing phosphate binders, 9.3 0.11 after phosphate bind-
ers were stopped, and to 10.0 0.6 during calcium carbonate
administration. In a few patients, we were unable to reduce the
dose of aluminum-containing phosphate binders because the
amount of phosphorus present in the diet was so large that the
dose of calcium carbonate required resulted in mild hypercal-
cemia; in some, serum calcium reached 11.5 mg/dl. At the
beginning of the study, the total amount of aluminum hydroxide
ingested by all 20 patients was 112 g/day; at the end of the
study, the amount was only 22 g/day. It appeared that treatment
with calcium carbonate was highly effective in approximately
70% of the patients. We measured sequential plasma aluminum
values in 6 of the 20 patients. In this group, mean serum
aluminum was 53 pg/liter. After replacing aluminum binders for
6 months with calcium carbonate, serum aluminum decreased
to an average value of 26 ig/liter. When calcium carbonate
induced hypercalcemia (serum calcium  11.5 mg/dl) in patients
ingesting large amounts of phosphorus, calcium carbonate
administration was discontinued, and the serum calcium re-
turned to normal values within 2 to 4 days.
Guidelines for calcium carbonate therapy
Using lessons from our experience, I recommend the follow-
ing. In a patient with severe hyperphosphatemia (serum phos-
phorus, 7 to 11 mg/dl), I first would try to decrease the serum
phosphorus by decreasing dietary phosphorus and by adminis-
tering an aluminum-containing phosphate binder. As soon as
the serum phosphorus fell to the range of 5 to 7 mg/dl, I would
give calcium carbonate. As I mentioned before, I would make
an effort not only to ascertain the total amount of phosphorus
ingested per day, but also the distribution of phosphorus intake
among the meals. I would start with 1 to 2 g of calcium
carbonate with each meal and, in accordance with the total
amount of phosphorus ingested, gradually increase the dose of
calcium carbonate until the serum phosphorus is normal. Then
850 Nephrology Forum
I would determine which of the patient's 3 daily meals provides
the largest amount of phosphorus, and I would increase the
dose of calcium carbonate accordingly. I would not increase the
dose of calcium carbonate, however, if the serum calcium rises
to 11 mgldl. If hyperphosphatemia persists in the presence of
calcium carbonate-induced hypercalcemia, I would add alumi-
num-containing phosphate binders. Patients in this category
generally are difficult to manage and require intensive medical
attention. I would have them seen frequently by a dietician and
I would make them aware of all the complications of hyper-
phosphatemia.
Removal of aluminum
Because most circulating aluminum is protein bound, the
clearance of aluminum by the artificial kidney is insignificant.
For this reason, the treatment of aluminum accumulation or
aluminum-induced osteomalacia requires removal of aluminum
from the body by chelating agents. Results of clinical trials and
studies in experimental animals with deferoxamine for the
treatment of aluminum-related osteodystrophy have been en-
couraging [67—69]; symptoms in patients generally improve
after several months of treatment. A comparison of bone
biopsies performed before and several months into therapy
usually demonstrates significant improvement in bone histomor-
phometry. The usual dose of deferoxamine is 4 to 6 g/week.
Many investigators prefer to give 2 g during the last 2 hours of
each dialysis; others prescribe 2 to 3 g twice weekly.
Deferoxamine usually is well tolerated, but episodes of hypo-
tension during hemodialysis have been reported [68]. Cataracts
also have developed in some patients, and retinitis has been
reported in a few patients receiving deferoxamine for iron
intoxication [70]. Periodic eye examinations therefore are ad-
visable for patients receiving deferoxamine over a long period.
The optimal duration of deferoxamine therapy is not yet known;
6 to 12 months probably is sufficient in most patients, but
further studies are required to answer this important question.
My collaborators and I have demonstrated that a microencap-
sulated carbon cartridge, attached in series distal to the
dialyzer, markedly improves the clearance of aluminum by the
artificial kidney. The addition of this device to the artificial
kidney might help to accelerate the recovery process [71].
Questions and answers
DR. SUSAN HOU (Renal Division, Michael Reese Hospital,
Chicago, Illinois): You noted that parathyroid hormone in-
creased somewhat during treatment with deferoxamine. Did
you find a difference in bone healing between patients who had
had a parathyroidectomy and those who had not? Was there
good healing in patients who had had a parathyroidectomy?
DR. SLATOPOLSKY: If a total parathyroidectomy has been
performed, the healing process will be greatly retarded and the
osteomalacia is likely to persist. Patients who have severe
secondary hyperparathyroidism in addition to aluminum-in-
duced osteomalacia should first receive treatment with defer-
oxamine; parathyroid hormone levels should be decreased
thereafter by a "medical" or surgical partial parathyroidecto-
my.
DR. Hou: Since you have made us aware of the problems of
aluminum, we have identified a number of patients who are
between the extremes of severe hyperparathyroidism and Se-
vere aluminum toxicity. What do you recommend for a patient
who has aluminum deposition in bone without osteomalacia,
that is, an asymptomatic patient who has aluminum deposition
not necessarily at the mineralization front, normal osteoid
width, and a positive deferoxamine test? Let's assume the
patient has a parathyroid hormone level 1.5 times normal for the
general population and an increment in serum aluminum of 200
p.g/liter in response to deferoxamine.
DR. SLATOPOLSKY: If the bone biopsy shows no deposition of
aluminum in the mineralization front and normal osteoid width,
I would not make the diagnosis of aluminum-induced osteoma-
lacia. Moreover, your hypothetical patient also is asymptom-
atic. Thus, I would recommend only close followup. If the
serum aluminum increases with time and the patient becomes
symptomatic, a second biopsy should be performed.
DR. JORDAN J. COHEN (Chairman, Department of Medicine,
Michael Reese Hospital): Am I correct in assuming that you
would treat patients for aluminum bone disease even without a
bone biopsy if they had a relatively modest elevation in para-
thyroid hormone level and a large increment in aluminum in
response to deferoxamine?
DR. SLATOPOLSKY: As I mentioned before, a bone biopsy is
the definitive test for establishing unequivocally the diagnosis of
aluminum-induced osteomalacia. However, if a patient does
have symptoms (such as severe bone pain), a positive deferox-
amine test, and low levels of parathyroid hormone, it is very
likely that not only aluminum accumulation but osteomalacia is
present. I would prefer to have a bone biopsy before I treat such
a patient, but with these findings I would treat the patient with
deferoxamine even if I cannot obtain a bone biopsy.
DR. COHEN: What is it about bone biopsies that makes this
test so observer dependent? Why couldn't any clinical labora-
tory make this test available?
DR. SLATOPOLSKY: Unfortunately, it is a special technique
that requires the right type of equipment and a bone pathologist
who has been trained in bone histomorphometry. There is a
significant difference between a pathologist who can look at a
bone biopsy and establish the diagnosis of malignancy, and a
bone pathologist who understands metabolic bone disease. The
specimen must be cut very thin, roughly 5 microns in thickness;
because minerals cannot be removed, special equipment is
necessary to cut calcified bone. Not all clinical laboratories are
equipped to perform this type of procedure.
DR. DAVID BUSHINSKY (Renal Section, Mitchell Hospital,
Chicago): The use of calcium carbonate to bind phosphate in
the intestinal tract might have complications that are as yet
unrecognized. Years ago we were made aware that the inges-
tion of excess calcium and absorbable alkali can lead to renal
insufficiency as a part of the "milk alkali syndrome" [72, 73]. If
we start to treat our patients with calcium carbonate early to
prevent phosphate retention, might we not inadvertently pro-
mote the progression of renal disease? Could this be a problem
analogous to the apparent accelerated decline of renal function
that can occur when large doses of oral 1 ,25(OH)2D3 are given
early in the course of renal insufficiency [74]?
DR. SLATOPOLSKY: As you realize, the studies that I have
reported with calcium carbonate were performed in patients
maintained on chronic hemodialysis; therefore, the GFR was
practically nonexistent. I do agree with you that if we use
calcium carbonate in patients with GFR between 10 and 20
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mt/mm, we have to follow them closely to prevent the devel-
opment of severe hypercalcemia. I would stress, however, that
these patients do not require very large amounts of calcium
carbonate because their serum phosphorus is not very elevated,
and they still can excrete a substantial amount of phosphorus in
the urine. Although we need more information, I believe that if
we follow these patients closely and avoid hypercalcemia, we
will elude the complications that you are rightly worried about.
DR. BusuINsKY: Have you seen evidence of metastatic
calcification in patients treated with calcium carbonate, espe-
cially those with hyperphosphatemia?
DR. SLATOPOLSKY: If I have a patient with severe hyperphos-
phatemia, I do not use calcium carbonate. First I correct the
levels of serum phosphorus with aluminum gels. Then, when
the serum phosphorus is in the range of 6 to 7 mg/dl, I introduce
calcium carbonate. I try to keep the calcium phosphate product
less than 70. I entirely agree with you that if a patient has a
serum phosphorus of 12 to 15 mg/dl and is treated with large
amounts of calcium carbonate, metastatic calcification is likely
to develop.
DR. BUSHINSKY: In addition to binding aluminum, deferoxa-
mine binds iron and trace metals. Have you seen iron or trace
metal depletion in patients treated with this agent for a pro-
longed period?
DR. SLATOPOLSKY: Deferoxamine does bind iron, and this
drug has been used for the treatment of iron intoxication. So far
I have not seen any patient who developed iron depletion. As a
matter of fact, I have seen an improvement in the hematocrit in
a few patients receiving deferoxamine. I obtain periodic ferritin
levels, and if they become abnormally low, I administer an iron
preparation.
DR. FREDRIC COE (Renal Section, Mitchell Hospital): Could
you expand on your interpretation of the experiment in which
parathyroidectomy increased the severity of the osteomalacia
induced by aluminum? Do you think that the aluminum is
affecting osteoblasts, and that parathyroid hormone in some
way makes the cells less responsive? Or do you think the
aluminum is acting as some kind of ligand at the mineralizaton
front to reduce enucleation of calcium salts?
DR. SLATOPOLSKY: As I mentioned before, good evidence
suggests that aluminum interferes with the number and function
of osteoblasts [47, 48]. Parathyroid hormone also works on
osteoblasts, and PTH receptors have been found in these
particular cells. Thus, the lack of PTH interferes with the
function of osteoblasts and the addition of aluminum makes
matters worse. Several studies have demonstrated that the lack
of parathyroid hormone aggravates the osteomalacia [57—60].
As a matter of fact, Lewis-Finch in our laboratory demon-
strated that the administration of aluminum to parathyroidecto-
mized rats with normal renal function produced severe
osteomalacia [751. Also, as you suggested, evidence indicates
that the formation of hydroxyapatite is impaired [76].
DR. MANMOHAN SINGH (Department of Orthopedic Surgery,
Michael Reese Hospital): What criteria do you use to define
aluminum bone disease? I ask this question because in many
biopsies, one can see aluminum in the body of the trabeculae
and not necessarily at the junction of the osteoid and the bone.
DR. SLATOPOLSKY: The most important criterion for the
diagnosis of aluminum-induced osteomalacia is the localization
of aluminum in bone and not the total amount of aluminum in
bone measured chemically. The presence of aluminum at the
mineralization front is of critical importance. As a matter of
fact, in our rats with aluminum-induced osteomalacia, the total
amount of aluminum in bone did not change significantly after
treatment with deferoxamine; however, histomorphometric
studies indicated a resolution of the osteomalacia [69]. The
mineralization front is a critical but small part of the bone.
Removing the aluminum from this area can produce a signifi-
cant improvement in the osteomalacic component, even though
total aluminum content in bone is not greatly affected.
DR. COHEN: You reasoned that dialysis fails to remove
aluminum very effectively because of intense protein binding.
How is it that the natural kidney is able to remove aluminum
much more efficiently? Why doesn't the same protein binding
impede renal clearance?
DR. SLATOPOLSKY: That is a very good question. Although I
am not aware of micropuncture studies in which aluminum
fluxes have been examined, I suspect that some aluminum is
secreted by the tubular epithelial cells.
DR. KA! LAU (Renal Division, Michael Reese Hospital): You
indicated that when plasma aluminum reaches levels of 50 to 80
tg/Iiter, parathyroid hormone release is suppressed, resulting in
a form of "medical parathyroidectomy." Why, then, should the
administration of aluminum have a different effect on the bone
in parathyroidectomized animals as compared with intact ani-
mals? Both should be functionally hypoparathyroid.
DR. SLATOPOLSKY: One must differentiate between total
parathyroidectomy and suppression in parathyroid hormone
release. Aluminum does not completely abolish the secretion of
parathyroid hormone, but it does decrease the concentration of
parathyroid hormone in serum. Thus, there is a significant
difference between the two situations that you mentioned.
DR. LAU: Quarles and colleagues have hypothesized that
aluminum might not be toxic to bone, that rather it merely seeks
out and deposits in bone that is already abnormal [52]. Would
you comment on this hypothesis?
DR. SLATOPOLSKY: The model developed by Quarles and
collaborators [52] is very different from the one observed in our
patients with chronic renal failure. They produced rickets by
depleting dogs of vitamin D. These animals, therefore, already
have an increased amount of osteoid and abnormal mineraliza-
tion front. When the authors gave aluminum, the metal was
incorporated into the osteoid tissue. The subsequent adminis-
tration of vitamin D cured the rickets. Thus, in this particular
experimental model, the accumulation of aluminum is simply an
epiphenomenon and is not the cause of osteomalacia. This
model is totally different from uremic patients who are not
depleted of 25—hydroxycholecalciferol.
DR. LAU: Has anyone done bone biopsies prospectively in
conjunction with deferoxamine infusion tests to assess the
frequency of false-positive and false-negative test results?
DR. SLATOPOLSKY: Yes. Nebeker and collaborators studied
102 patients maintained on chronic hemodialysis [28]. These
studies demonstrated that the diagnostic capability of the
deferoxamine infusion test could be improved by coupling it
with determinations of iPTH. If deferoxamine administration
results in an increment in serum aluminum of greater than 200
slEq/ml and the serum iPTH level remains below 200 piEq/ml,
the sensitivity of the test for the diagnosis of aluminum bone
disease is 79% and the specificity, 73%.
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DR. SERAFINO GARELLA (Renal Division, Michael Reese
Hospital): You discussed the effects of aluminum overload on
renal osteodystrophy and on parathyroid dysfunction. Alumi-
num overload is also thought by many to be the cause of
so-called dialysis encephalopathy, and to be a contributing
factor in some types of anemia in patients with end-stage renal
disease. What has been your experience with the effects of
deferoxamine on dialysis encephalopathy and anemia?
DR. SLATOPOLSKY: The majority of patients who have devel-
oped aluminum-induced encephalopathy appear to have re-
ceived large amounts of aluminum during dialysis because of
high concentrations of aluminum in the dialysate. Most dialysis
units now use reverse osmosis or demineralized water to
remove aluminum, so the incidence of aluminum-induced en-
cephalopathy is greatly diminished. Only a few patients with
severe encephalopathy have improved with deferoxamine treat-
ment. It is apparently difficult to remove large amounts of
aluminum from the brain. With respect to anemia, I have
observed an improvement in the hematocrit of a few patients
after deferoxamine treatment, and evidence exists indicating an
important role for aluminum in the development of anemia
[77—78].
DR. GARELLA: In your studies of the effects of aluminum on
dispersed parathyroid cells, you demonstrated an inverse cor-
relation between the concentration of aluminum in the medium
and the rate of release of parathyroid hormone. I assume that all
the aluminum in the supernatant of this preparation was un-
bound. Consequently I'm wondering whether it is fair to
compare the aluminum concentration in the medium to that in
patients, because only 10% or so of the aluminum in plasma is
unbound. Is it possible that a much higher concentration of
aluminum might be necessary to exert a depressive effect on the
release of parathyroid hormone in vivo?
DR. SLATOPOLSKY: In our studies we have observed that very
low concentrations of aluminum impair the release of parathy-
roid hormone. A significant suppression was observed with
only 50 to 80 xg/liter [41]. Patients with aluminum accumulation
can have serum aluminum between 500 and 1000 jxg/liter after
the administration of deferoxamine. Moreover, such patients
have been exposed to aluminum for many months or years and
it is known that the parathyroid glands do accumulate aluminum
[44]. Thus it is difficult to compare concentrations of serum
aluminum obtained in vivo with in-vitro levels from our studies.
If 10% to 15% of circulating aluminum is ultrafiltrable, and if the
serum aluminum level is 500 pg/liter, ultrafiltrable aluminum
would be in the range of 50 to 70 gIliter, an amount similar to
that producing inhibition of PTH release in vitro.
DR. JAMES BOURDEAU (Renal Division, Michael Reese Hos-
pital): Why is muscle pain a symptom of aluminum-induced
bone disease? How does treatment affect this symptom?
DR. SLATOPOLSKY: I don't believe that the pathophysiology
of the muscle pain is known. Although patients frequently
complain of muscle pain, microfractures secondary to osteoma-
lacia can be present. Often it is difficult to determine whether
these patients have bone or muscle pain. Regardless of the basic
mechanism, I have been impressed with the use of deferoxa-
mine and I have observed the disappearance of the symptoms in
several patients after 2 to 4 months of treatment.
DR. COHEN: As you noted, patients with aluminum-induced
bone disease and osteomalacia often respond to 1 ,25(OH)2D3
with a brisk increase in serum calcium. Indeed, this response
might limit the patient's ability to tolerate vitamin D therapy. Is
there a physiologic explanation for this observation?
DR. SLATOPOLSKY: Yes; l,25(OH)2D3 increases calcium ab-
sorption and usually results in positive calcium balance. Alu-
minum deposited in the mineralization front prevents the newly
available calcium from depositing in this critical part of the
bone. Consequently, severe hypercalcemia can develop.
DR. STEVEN BORKAN (Renal Fellow, University of Chicago):
What is the evidence that I ,25(OH)2 vitamin D increases not
only intestinal calcium absorption but intestinal aluminum
absorption? These actions might increase the risk of aluminum
osteomalacia in patients treated with both aluminum hydroxide
and l,25(OH)2 vitamin D.
DR. SLATOPOLSKY: This subject requires further investiga-
tion. However, Drueke and collaborators demonstrated that
exogenous administration of I ,25(OH)2D3 increases plasma
concentration of aluminum [79].
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